@inproceedings{inproceedings, title  = {{A Phase 3, Randomized, Open-Label, Multicenter, Global Study of Efficacy and Safety of Durvalumab in Combination with Gemcitabine plus CiSPLATiN (G plus C) for Neoadjuvant Treatment Followed By Durvalumab Alone for Adjuvant Treatment in Muscle-Invasive Bladder Cancer (MiBC) (NiAGARA)}},

 url = {{}},

 year = {{2020}},

 month = {{1}},

 author = {{Kuebler HR and Powles T and Meeks JJ and Galsky M and van der Heijdens MS and Nishiyama H and Al-Ahmadie H and Gupta A and Ye J and Donegan S and Ghiorghiu D et al}},

 volume = {{43}},

 journal = {{ONCOLOGY RESEARCH AND TREATMENT}},

 pages = {{82-82}},

 note = {{Accessed on 2024/12/22}}}